

Transcutaneous afferent patterned stimulation reduces essential tremor symptoms through modulation of neural activity in the ventral intermediate nucleus of the thalamus

Luu, Cuong P.^{1,2}, Ranum, Jordan², Youn, Youngwon^{1,2}, Perrault, Jennifer L.², Krause, Bryan³, Banks, Matthew³, Buyan-Dent, Laura⁴, Ludwig, Kip A.^{1,2}, Lake, Wendell B.^{1,2}, & Suminski, Aaron J.^{1,2}

¹Department of Neurological Surgery, University of Wisconsin-Madison

²Wisconsin Institute for Translational Neuroengineering, University of Wisconsin-Madison

³Department of Neuroscience, University of Wisconsin-Madison

⁴Department of Neurology, University of Wisconsin-Madison

Address for Correspondence:

Aaron J. Suminski

1111 Highland Ave, Rm. 3555

Madison, WI 53705

Keywords: Essential Tremor, Human, Peripheral Nerve Stimulation, Neuromodulation, VIM, cerebello-thalamo-cortical network, Deep Brain Stimulation

Words in Abstract: 217

Total Words: 2902 (Introduction, Results, Discussion, Conclusion)

Number of Figures: 4 main figures + 8 supplementary figures

Number of Tables: 1

Abstract

Essential tremor (ET), the most common movement disorder in adults, presents with involuntary shaking of the arms during postural hold and kinetic tasks linked to dysfunction in the cerebello-thalamo-cortical (CTC) network. Recently, transcutaneous afferent patterned stimulation (TAPS), applied through a wrist-worn device, has emerged as a non-invasive therapy for medication refractory ET. However, its mechanism remains unclear. We hypothesize that TAPS reduces tremor through modulation of the VIM thalamus in the CTC network. Employing refractory ET patients seeking VIM deep brain stimulation (DBS), we quantified clinical tremor improvement following TAPS treatment in a pre-operative setting, followed by intra-operative, microelectrode recording of the contralateral thalamus with concurrent TAPS treatment on and off. After one preoperative session, TAPS significantly reduces upper limb tremor, with asymmetric effect favoring the treated limb and greatest improvement tending to kinetic tremor. The magnitude of TAPS-related tremor reduction demonstrates a positive correlation with the modulation of alpha and beta band LFPs in the VIM. TAPS also modulated spiking activity in the VIM, though it was uncorrelated with the degree of tremor reduction. Of note, TAPS related modulation of LFPs and spiking activity was greatest near the optimal placement location for DBS lead in treating ET. In sum, TAPS likely reduces tremor in ET by modulating the VIM and connected nodes in the cerebello-thalamo-cortical pathway.

1 Manuscript

3 Introduction

4 Essential tremor (ET) is the most common movement disorder in adults, and its impact is rising
5 as a greater share of the world population age.^{1,2} ET patients experience debilitating symptoms
6 from involuntary, rhythmic action tremor of the arms, though shaking can also involve the head,
7 voice, and legs.^{3,4} These action tremors often involve two clinically distinct types with intrinsically
8 different frequency: kinetic tremors, typically under 6 Hz, and postural tremors, which range
9 from 6 to 12 Hz.^{3,5-9} Their exact etiology remains unclear, but, complementary evidence from
10 postmortem histology^{10,11}, imaging¹², and electrophysiological¹³ studies point to dysfunction in
11 the cerebello-thalamo-cortical (CTC) network—a network that links the deep cerebellar nuclei to
12 the motor cortex via the motor and sensory thalamus, including the ventral intermediate (VIM)
13 nucleus. The disruption of this network hinders one's ability to evaluate and refine goal directed
14 movement.¹⁴⁻²⁰

15
16 There remains a significant gap in the treatment of ET. Frontline medical intervention with
17 primidone and propranolol may improve tremor to a modest extent, but about 50% of patients
18 stop medications due to side effects.^{21,22} Surgery for deep brain stimulation (DBS) targeting the
19 VIM demonstrates a 60-75% reduction in tremor, yet up to 86% suffer ataxia, dysarthria, or
20 dysgeusia and 15-73% eventually lose tremor control.^{23,24} The concerns of side effects, therapy
21 habituation, and cost from DBS deter approximately half of eligible candidates.²⁵ Thus, VIM
22 DBS is generally reserved for patients with severe, debilitating ET. Recently, a less invasive
23 alternative, magnetic resonance-guided focused ultrasound (MRgFUS), has shown promise in
24 treating moderate to severe, refractory ET by creating a lesion in the VIM.²⁶⁻²⁹ Despite its safety
25 and efficacy, MRgFUS adoption has also remain limited due to its need for specialized
26 equipment, irreversible nature, and high relapse rate.³⁰ Taken together, the limitations of current
27 therapies leave many ET patients, especially those with mild to moderate symptoms, without
28 effective treatment options.

29
30 In response to these limitations, transcutaneous afferent patterned stimulation (TAPS™)
31 emerged as a non-invasive, on-demand therapy to reduce hand tremor in ET patients.³¹ TAPS
32 applies electrical bursts that alternate between the median and radial nerves on the wrist,
33 leveraging afferent projections from these nerves to stimulate the VIM. Importantly, electrical
34 stimulation of the median nerve is known to directly modulate neural activity throughout the
35 somatosensory thalamus, including the VIM.³²⁻³⁴ The alternating burst of TAPS, whose
36 frequency is tuned to the tremor frequency of each patient, is intended to disrupt synchronized,
37 pathological firing of VIM neurons through a process known as coordinated reset.³⁵ TAPS has
38 gained FDA approval for ET treatment, demonstrating efficacy in a randomized controlled trial
39 and a 38-83% tremor reduction lasting about one hour after each session.^{36,37} Its tremor-
40 reducing effects have been shown to accumulate over months of treatment, with no habituation
41 and minimal side effects.³⁸

42
43 As proposed in theory, TAPS achieves tremor reduction by desynchronizing pathological,
44 oscillatory neural activity in the CTC network.³⁹ However, outside of data showing clinical
45 improvement and a small FDG-PET/ CT study, there is limited evidence elucidating the
46 underlying mechanism of TAPS and its potential impact on the brain.^{40,41} Here, we examined
47 what effect TAPS has on the clinical components of ET and how it may modulate the CTC
48 network. We hypothesized that TAPS would modulate the VIM thalamus in patients who see
49 tremor reduction benefits. Our results provide strong evidence suggesting that tremor
50 improvement resulting from TAPS therapy is related to modulation of neural activity in the CTC
51 network, in particular, modulation of alpha band local field potentials (LFP).

52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102

Results

Study demographics, design, and TAPS

To prospectively study the effect of TAPS across tremor types and on thalamus activity, we enrolled 9 adults (2 female, Mean age \pm SD: 65 ± 7 years) with medication refractory ET seeking DBS placement in the VIM. Demographic, medical history, and study-related measures are reported in Table 1. Using the Essential Tremor Rating Assessment Scale (TETRAS), all subjects presented with moderate hand tremor scores (Mean \pm SD of spiral drawing score: 2.8 ± 0.8 ; upper limb tremor: 2.3 ± 0.5) approximating an average tremor amplitude of 5 cm. When surveyed with the Quality of Life in Essential (QUEST) questionnaire, tremor was present during most of patients' waking hours (Mean \pm SD: $82.1 \pm 15.4\%$), with the greatest impact on hobbies/leisure activities (Mean \pm SD: $85.2 \pm 15.5\%$) and general physical activities (Mean \pm SD: $66.1 \pm 25.2\%$).

Patients underwent the study in 2 phases, in which they donned a wrist-worn stimulator and received standard TAPS treatment on their dominant limb (Fig. 1A, B; see Methods 1.2). TAPS treatment was personalized for each participant at their tremor frequency (Mean \pm SD: 5.4 ± 1.3 Hz) and at the maximum tolerable stimulation amplitude (Mean \pm SD: 7.0 ± 1.1 mA), calibrated according to the manufacturer's instructions. These stimulation parameters were held constant between both the pre-operative and intra-operative phases. Phase 1, pre-operative, further involved the assessment of tremor severity using the TETRAS before and after TAPS treatment (Fig. 1C). Phase 2, intra-operative, occurred during the stereotactic operation to place DBS electrode in the VIM, a standard surgery to treat refractory ET (Fig. 1D). Of note, we removed subject 8 from subsequent analysis because the individual reported an atypical, long-term tremor suppression for one month after their TAPS treatment in phase 1.

Individual and aggregated upper limb tremor tasks significantly improved in the dominant limb following TAPS treatment

Our first goal was to quantify the therapeutic effect of TAPS. We scored tremor severity using the 5 upper limb tasks in TETRAS before and after TAPS treatment, calculating tremor improvement as the difference in pre- and post-treatment scores (see Methods 1.3). Consistent with previous randomized controlled trials³⁶, TAPS significantly improved the average total upper limb TETRAS score for the treated limb (0.61 , $p=0.008$). Interestingly, we also found that TAPS resulted in a significant improvement in the average total upper limb TETRAS score of the untreated limb (0.35 , $p=0.008$); however, improvement in the treated, dominant limb, was significantly greater than the untreated limb ($p=0.047$) (Fig. 2A). Given that ET is known to manifest with distinct postural and kinetic tremor components, we were also interested in examining TAPS related improvements in the individual upper limb tremor tasks. The treated hand showed a significant improvement in the forward postural hold (0.625 , $p=0.016$), spiral drawing (0.875 , $p=0.039$), and dot approximation (0.563 , $p=0.031$) tasks with trends toward significant effects in the lateral postural ($p=0.063$) and kinetic ($p=0.063$) tremor measures (Supplementary Fig. S1). In contrast, the untreated limb showed no significant improvement in any of the individual tasks ($p>0.05$). We further analyzed handwriting, though separately as we did not collect handwriting data from the untreated, non-dominant limb, and found a significant improvement in handwriting tremor score resulting from TAPS (0.79 , $p=0.002$) (Supplementary Fig. S2).

TAPS therapy enhanced improvement of kinetic tremor in the dominant limb

103
104 Given the significant reduction in tremor severity observed for both limbs, we were interested in
105 isolating the effect of TAPS to the treated limb. We captured this through the fractional tremor
106 reduction (fTR) score, calculated as a difference in average upper limb tremor improvement
107 between the treated and untreated limb with normalization to the untreated limb value (Eq. 1).
108 fTR ranged from -0.67 to 5.00, showing that subjects' responses to TAPS had a wide dynamic
109 range corresponding to observed qualitative tremor improvement (Fig. 2B, C). Here, half of the
110 subjects exhibited $fTR \geq 1$ (i.e. double the tremor improvement in the treated limb compared to
111 the untreated limb).

112
113 To continue the examination of how TAPS may impact the two components of ET, we explored
114 the differential impact of TAPS on tasks that were grouped into either the kinetic or postural
115 tremor components. We questioned if initial tremor severity correlated with fTR as tremor
116 severity may be predictive of ET onset and progressive atrophy along neural pathways.^{42,43} We
117 used the pre-treatment TETRAS scores as a proxy for initial tremor severity. Regression
118 analysis found no relationship between fTR scores and tremor severity for postural or kinetic
119 tremor (Fig S3). Next, we explored if TAPS exhibited differential improvement in either kinetic
120 tremor or postural tremor. We discovered that improvement in kinetic tremor scores of the
121 treated limb displayed a significant positive relationship with fTR, explaining 94.3% of the
122 variability ($F(3,4)=39.623$, $p=0.002$) (Fig. 2D). In contrast, there was no relationship between
123 improvement in postural tremor and fTR ($p=0.967$) (Fig. 2E).

124 125 ***Fractional tremor reduction in the dominant limb directly correlates with LFP modulation*** 126 ***in the VIM***

127
128 Next, to understand TAPS's therapeutic mechanism, we investigated if therapeutic effect was
129 mediated by changes in neural activity within a prominent node in the CTC network, the VIM.
130 During each patient's awake DBS implant surgery, we advanced 3 microelectrodes along a
131 trajectory targeting the VIM, recording at selected depths in and around the VIM while TAPS
132 treatment was ON and OFF. Subsequently, we processed the recordings for the power of the
133 LFP at different frequency bands from 0 to 200 Hz, and quantified the modulation index of LFP
134 (MI_{LFP}) as the fractional difference in power between the ON and OFF states (Fig. 3A, B). Since
135 we suspected that TAPS may act on the same neural substrate as DBS, we performed an initial
136 survey of the relationship between MI_{LFP} and distance from the final implant location of the DBS
137 lead (i.e. the distal edge of the most distal contact on the DBS lead; see Methods 1.4).
138 Regression analysis, however, found no relationship between MI_{LFP} in any frequency band and
139 distance from the DBS lead implant location (Supplementary Fig. S4). We examined this
140 relationship more deeply by parsing MER recordings that were putatively made within the VIM
141 (Fig. 3C, ≤ 5 mm from implant location) or outside of it (>5 mm). Here, regression analysis found
142 that, only within the VIM, the alpha band MI_{LFP} was strongly modulated closer to the DBS
143 implant location ($R^2=0.1221$, $F(1,52)=8.371$, $p=0.006$) (Fig. 3D, F). In contrast, no relationship
144 between MI_{LFP} and distance to implant location was found outside of the VIM in any frequency
145 band (Fig. 3 E, F; Supplementary Fig. S5), suggesting that TAPS and DBS may share a
146 common mechanism for mitigating tremor.

147
148 Since tremor improvement due to TAPS, measured by fTR, varied widely among patients, we
149 examined if there was a relationship between fTR and changes in neural activity quantified by
150 MI_{LFP} across different frequency bands. Within the VIM, regression analysis found that patients
151 who experienced the largest fTR due to TAPS had significantly increased MI_{LFP} in only the
152 alpha ($F(1,52) = 15.313$, $p < 0.001$) and beta bands ($R^2=0.255$, $F(1,52)=19.16$, $p < 0.001$) (Fig. 3G,
153 l). For recording locations outside the VIM, there was no relationship between tremor reduction

154 and MI_{LFP} for any band (Fig. 3H, I; Supplementary Fig. S6). Notably, this effect was specific to
155 tremor reduction as measured by fTR; a separate regression analysis showed no relationship
156 between MI_{LFP} within the VIM and total tremor improvement in the treated upper limb (i.e. no
157 normalization by effect in the untreated limb).

158 159 ***TAPS suppresses multiunit spiking in the VIM, though effect was homogenous among*** 160 ***patients***

161
162 In addition to thalamic LFP, we also examined the modulation of multiunit spiking activity in
163 response to TAPS treatment. One representative sample, recorded within the VIM 0.5 mm from
164 the final implant location, showed a pronounced reduction in spike rate during TAPS treatment
165 (Fig. 4A, B). We limited our analysis to recording depths within the VIM (i.e. ≤ 5 mm from the
166 final implant location) where the minimum firing rates was at least 1 Hz while TAPS was OFF.
167 We used a resampling procedure to estimate the most likely multiunit firing rate. This was
168 necessary because many time series had different durations due to removal of motion artifacts
169 (Fig. 4C, D). In the 37 recordings that met this criterion, we characterized the modulation index
170 of spikes (MI_{Spikes}) as the fractional difference in spike counts between the ON and OFF states
171 of TAPS. MI_{Spikes} significantly decreased closer to the final implant location, with trend toward
172 $MI_{Spikes} = -1$ indicating that TAPS suppressed spiking activity to near 0 ($R^2=0.104$,
173 $F(1,35)=5.197$, $p=0.029$) (Fig. 4E). No significant relationship was observed between MI_{Spikes}
174 and isolated tremor improvement ($p=0.777$) (Fig. 4F). At distances >5 mm, MI_{Spikes} ranged from -
175 1 to 0.5, but it did not exhibit a significant relationship with either distance from implant location
176 or isolated tremor improvement ($p=0.768$ and $p=0.949$, respectively).

177 178 ***Discussion***

179
180 In the effort to find non-invasive therapy for ET, transcutaneous afferent patterned stimulation of
181 the median and radial nerves near the wrist (i.e. TAPS) has been shown to reduce limb tremors,
182 but its mechanism of action remains unclear. Putatively, stimulation alternating between the
183 median and radial nerves serves to provide a desynchronizing input to the sensorimotor
184 thalamus (i.e. VIM) via projections ascending in the dorsal column and/or spinothalamic
185 pathways. The VIM links cerebellar output with the sensorimotor cortex and serves as a major
186 node in the CTC network, the hypothesized locus of dysfunction in ET¹⁰⁻¹³. Given this
187 anatomical substrate and that lesional therapies²⁶⁻²⁹ and DBS^{23,24} target the VIM for treatment of
188 ET, we hypothesized that VIM is a likely site of the therapeutic effect of TAPS. Here, we
189 demonstrated that TAPS of the median and radial nerves directly modulate the activity of both
190 local field potentials and spiking activity in the VIM thalamus. Specifically, our data
191 demonstrates that patients who have the greatest modulation of alpha and beta LFP caused by
192 TAPS experienced the largest reduction in tremor symptoms. Additionally, sites exhibiting the
193 largest modulation of both LFP and spiking activity are generally located closest to the
194 placement of the DBS lead for treatment of ET (annotated as the distance from implant location
195 and marked by the distal edge of the distal electrode on the DBS lead). Finally, our data further
196 suggested that TAPS have an asymmetric effect on tremor reduction in different subtypes, with
197 an enhanced effect on kinetic tremor relative to postural tremor in the treated limb.

198 199 ***TAPS acts on the cerebello-thalamo-cortical network***

200
201 There is strong evidence linking dysfunction throughout the CTC network, particularly
202 thalamocortical circuits, to ET.^{13,44-48} For example, Kane et al. reported increased theta (4-8Hz)
203 and alpha (8-12Hz) LFP power in thalamic nuclei receiving cerebellar input (i.e. VIM) compared
204 to nuclei receiving input from the basal ganglia or somatosensory afferents. In conjunction,

205 LFPs recorded from the VIM demonstrated increased synchrony in ET patients compared to
206 individuals diagnosed with other neurodegenerative diseases⁴⁶, and motor cortex alpha LFP
207 power is altered in ET patients when compared to healthy controls.¹³ Moreover, electrical
208 stimulation of the median nerve is known to modulate neural activity throughout the CTC
209 network with the most direct effects being found in the somatosensory thalamus.^{32–34} Our data
210 bridge the evidence describing CTC network dysfunction in ET and a putative therapeutic
211 mechanism for TAPS, that is the modulation of neural activity in VIM. Notably, we show that
212 TAPS of the median and radial nerves increased modulation of VIM alpha and beta bands LFP
213 in subjects with higher fTR (Fig 3G, I), indicating a mechanistic role for VIM in reducing tremor.
214 This effect was limited to the VIM as no LFP modulation was observed at distances >5mm from
215 the location of the implanted DBS lead (Fig 3E, H). Notably, modulation of multiunit spiking
216 activity was also only observed within the VIM; but, unlike alpha and beta LFP, had no
217 relationship to reduction of tremor symptoms (Fig 4E, F). The dissociation between LFP and
218 spiking activity modulation's relationship to tremor reduction (i.e. fTR) is particularly interesting
219 and potentially meaningful given their distinct roles.⁴⁹ Specifically, Low-frequency field potentials
220 typically reflect summed synaptic currents—potentially representing inputs to an area—while
221 single/ multiunit activity likely represents outputs. In this light, the mechanism of TAPS may be
222 thought to act on the CTC network more broadly via the VIM, and not on local neural
223 populations in the VIM alone.

224
225 In validating our neural data, we believe that these results are not confounded by artifacts from
226 TAPS applied at the wrist. First, raw time series showed no evidence of stimulation artifacts (Fig
227 4A, B; Supplementary Fig. S8). Second, modulation of neural activity related to tremor reduction
228 (i.e. fTR) was only found in a spatially defined region, putatively within the VIM. Given the small
229 range between the most dorsal and ventral recording locations (~10mm), we would expect any
230 presenting stimulation artifact to appear at all depths—that was not seen. Finally, the wrist
231 stimulation device is wireless and battery-powered with a localized, bipolar electrode geometry,
232 mitigating the effect of ground loop contamination and broad spread of the applied electric field.

233 234 ***Heterogeneous tremor improvement in response to TAPS treatment***

235
236 In our study, we observed that TAPS significantly improved tremor in both the treated *and*
237 untreated limb. As described above, the effect of TAPS is putatively due to modulation of the
238 CTC network via the VIM contralateral to the treated limb. The observed decrease in tremor in
239 the untreated limb, however, is unexpected and its origin is unclear. Anecdotal observations and
240 some reports have suggested that unilateral VIM DBS results in a significant tremor reduction in
241 the arm ipsilateral to the implant⁵⁰, but this ipsilateral benefit of DBS remain controversial and
242 inconclusive.^{51–53} It is possible that the tremor improvement observed in the untreated limb of
243 our patients may have resulted from a sham/ placebo effect. This interpretation is based on
244 results from recent randomized controlled trial studying the effect of TAPS.³⁶ Here, Pahwa et. al
245 reported that subjects who had received TAPS treatment displayed tremor improvement similar
246 in magnitude to what we see in the treated limb of our subjects (Fig. 2A). Of significance, we
247 see further concordance in the magnitude of tremor improvement between Pahwa et. al's
248 subjects who received sham treatment and the untreated limb of our subjects. Thus, we believe
249 that the improvement in the untreated limb, while statistically significant, is a sham effect.
250 However, we did not test sham-treatments to provide conclusive evidence; future sham-
251 controlled studies assessing tremor improvement in both the treated and untreated limb should
252 be performed to demonstrate if unilateral TAPS exerts a bilateral effect on upper limb tremor.

253
254 Due to the unknown origin of tremor reduction in the untreated limb, we used a fractional
255 difference measure, fTR, to estimate the effect of TAPS in the treated limb over and above the

256 effects common to both limbs. Importantly, tremor improvement scores computed with fTR
257 stratified patients into low and high responders in a similar proportion to previously published
258 methods (i.e. half of the patients were high responders with $fTR \geq 1$).^{37,38} We found that tremor
259 reduction measured by fTR was primarily driven by improvements in kinetic tremor (assessed
260 by spiral drawing, finger-to-nose movement, and dot approximation) rather than postural tremor.
261 This is an interesting result especially considering that kinetic and postural tremors have
262 different characteristic frequencies of oscillation, <6Hz and 6-12Hz, respectively.^{3,7-9} It is
263 possible that the alternating burst frequency of TAPS could be modified to directly target various
264 tremor subtypes and thereby personalize treatment based on an individual's symptom profile.

265
266 Consistent with prior studies exploring tremor reduction due to TAPS³⁶⁻³⁸, we found that patients
267 experienced varied degrees of tremor improvement. We explored a few possible explanations
268 for the observed heterogeneity in response to TAPS. First, it is possible that engagement of the
269 median and radial nerves at the wrist varied between patients; improper alignment of the
270 stimulation electrode with the underlying anatomy or inadequate stimulation intensity could have
271 diminished therapeutic effects. Here, wristband sizing, positioning, and stimulation parameters
272 for TAPS were determined based on manufacturer's instructions (i.e. tremor frequency
273 measured during postural hold and stimulation amplitude set as the maximum tolerable current
274 for 40 minutes of treatment). Importantly, all subjects verified the presence of paresthesia, not
275 muscle contraction, in the median and radial nerves' hand dermatomes with TAPS activation
276 during both phases of the experiment. The presence of paresthesia referred to the fingertips,
277 lacking reported pain or visible muscle recruitment, indicates engagement of large myelinated
278 proprioceptive and cutaneous afferents (A-alpha and A-Beta fibers) in the median and radial
279 nerve trunks.^{54,55} Therefore, subjects likely experienced adequate target nerves engagement.
280 Second, dysfunction in the transmission of sensory information from the peripheral nerve to the
281 central nervous system could contribute to varied efficacy of TAPS. Such dysfunction may be
282 due to the severity of disease or another unknown factor. Importantly, our data showed no
283 relationship between fTR and pre-treatment tremor severity, and no patients in our cohort
284 reported sensory dysfunction. Thus, we expect sensory dysfunction did not impact our results.
285 We did not, however, explicitly characterize proprioceptive or somatosensory acuity in our
286 patients, and are not able to definitively rule out sensory deficits as a factor in the
287 heterogeneous response to TAPS. Thus, relationship between the sensory perception of TAPS
288 and the degree of tremor reduction remains an open question. Full exploration of the effect of
289 the perceived sensation and its relationship to fiber type recruitment will likely require further
290 extra-operative experiments.

291 292 **Limitations**

293
294 We acknowledge that there are several limitations regarding this work and the conclusions
295 drawn. First, our small cohort size reflects the exploratory nature of this research, as TAPS's
296 effects on CTC network activity had not been previously documented. Future confirmatory
297 studies with pre-registered methodology will be essential to validate and expand on the findings
298 elaborated here. Second, research using intraoperative neural recordings faces inherent
299 limitations due to the clinical priorities of the surgery. For example, the use of sedatives during
300 the DBS procedure may have influenced microelectrode recordings. This concern is likely
301 muted, however, due to the rapid clearance of remifentanyl and its minimal effect on neural
302 activity.^{56,57} In addition, we also limited surgery duration to minimize infection risks and patient
303 discomfort; thus, we could not test multiple stimulation parameters at each recording depth.
304 Instead, we focused on recording neural activity resulting from TAPS treatment at a single
305 current amplitude and alternating burst frequency. Future work that aims to explore or optimize
306 the effect of stimulation parameters on VIM neural activity should employ chronically implanted

307 recording methods. Such methodology would track long-term changes, enabling more robust
308 analyses to address the cross-sectional limitations of this study. For example, larger datasets
309 from such studies could also support advanced machine learning models to predict and
310 optimize TAPS-related tremor reduction on an individual basis. Third, the lab-based
311 quantification of TETRAS tremor scores may have induced stress in patients through a "white
312 coat effect," potentially biasing our measures of TAPS efficacy compared to home use and
313 contributing to the observed response heterogeneity. Though, this is unlikely because the
314 heterogeneity in tremor reduction captured by fTR matches the spread in therapeutic effect
315 seen by patients with long-terms home use of TAPS.³⁸ Finally, our results should be applied
316 with caution when placed in the context of other non-invasive therapies using peripheral nerve
317 stimulation to treat the symptoms of ET as the mechanism of action described here may be
318 unique to TAPS.

319
320 **Conclusion**

321 TAPS significantly reduced upper limb tremor severity in our cohort of medically refractory ET
322 patients, with the treated limb showing greater improvement in kinetic tremor tasks. The
323 therapeutic effect was associated with modulation of alpha and beta band local field potentials
324 in VIM thalamus, with the greatest modulation proximal to the DBS implant site. In contrast,
325 while VIM multiunit spiking activity was also modulated, these changes did not correlate with
326 tremor reduction. This dissociation between field potentials and spiking activity suggests TAPS
327 may achieve therapeutic benefit by modulating multiple nodes of the CTC network connected to
328 VIM, potentially including the motor cortex and cerebellum, rather than through direct effects on
329 VIM alone.

330 **Material and methods**

331

332 *1.1 Subject Inclusion & Exclusion Criteria*

333

334 We prospectively enrolled 9 adults with medication refractory ET seeking DBS placement in the
335 VIM. Key inclusion criteria were (1) age between 18 and 85 years old, and (2) a baseline,
336 dominant hand score of 2+ on TETRAS item 6 Archimedes spiral drawing. Spiral drawing score
337 served as one proxy for initial tremor severity, where a score of 2+ was selected to match the
338 severity of subjects recruited in past studies.^{36,58} Subjects were excluded if they (1) were
339 pregnant or (2) had cognitive disability impairing understanding of the consent process or
340 experimental directions. All subjects provided written informed consent. The study was
341 approved by the Institutional Review Board (IRB) at the University of Wisconsin – Madison (IRB
342 ID: 2018-1052).

343

344 *1.2 Transcutaneous Afferent Patterned Stimulation (TAPS)*

345

346 We fitted each subject with a wrist-worn stimulator (Cala TWO band, Cala Health, CA, USA) to
347 deliver TAPS on their dominant upper limb. The band hosted pad electrodes targeting the
348 median and radial nerves, in addition to an electrode on the dorsal wrist for electrical return (Fig.
349 1A). After donning the device, the maximum tolerable stimulation current amplitude (mA) and
350 alternating burst frequency (Hz) were calibrated for each subject. To attain the maximum
351 tolerable current, stimulation was increased in 0.25 mA increments until the subject reported
352 paresthesia in both the median and radial nerves' hand dermatomes. The final current was the
353 highest amplitude the subject reported that they could tolerate for 40 minutes. As for the
354 alternating burst frequency, it was measured by on-board accelerometry and determined as the
355 higher of two tremor frequencies after each subject had performed the forward and lateral
356 postural hold tasks. The alternating burst frequency controlled how many alternating stimulation
357 sets are delivered to the median and radial nerves per second (Fig. 1B). Stimulation on each of
358 the median or radial nerve was delivered in biphasic pulses at 150 Hz, each phase lasting 300
359 μ s with a 50 μ s interphase period.

360

361 *1.3 Phase 1: Pre-operative Quantification of Tremor Changes Following TAPS*

362

363 Tremor severity was evaluated using TETRAS, picked for its high sensitivity to tremor changes
364 and reliability between raters.⁷ TETRAS contained 9 performance items to rate action tremor in
365 the head, face, voice, limbs and trunk from 0 (no tremor) to 4 (severe tremor) in increments of
366 0.5. Tremor exhibiting a higher amplitude (cm) scored higher in severity. In addition, tremor
367 impact on life quality were also surveyed using the QUEST as these measures hold a modest
368 insight into tremor severity.⁵⁹ We scored tremor severity for the dominant and non-dominant
369 limb using TETRAS before and after 40 minutes of TAPS delivered to the wrist of the dominant
370 limb (Fig. 1C). Total upper limb tremor improvement was taken as an average of the differences
371 in scores before and after treatment in 5 tremor tasks described by TETRAS items 4, 6, and 8
372 (Eq. S1). TETRAS item 4 tested (1) forward postural, (2) lateral postural, and (3) kinetic finger-
373 to-nose tremors; item 6 tested (4) spiral drawing; and, item 8 tested (5) dot approximation
374 tremor.

375

376 *1.3.2 Characterizing Tremor Improvement in the Treated Limb*

377

378 In addition to computing tremor improvement for each limb separately, we were interested
379 isolating the effect of TAPS in the treated limb from those that were potentially common to both
380 limbs. Here, we used tremor improvement in the untreated limb as a within-subject

381 normalization factor for the quantification of how TAPS affected tremor in the treated limb.
382 Subsequently, the fTR of the treated limb following TAPS was computed as a fractional
383 change in tremor improvement of the treated limb relative to the untreated limb:

$$385 \text{ fractional Tremor Reduction (fTR)} = \frac{\text{Improvement}_{\text{treated limb total}} - \text{Improvement}_{\text{untreated limb total}}}{\text{Improvement}_{\text{untreated limb total}}} \quad (\text{Eq. 1})$$

386
387 Therefore, fTR estimates the effect of TAPS in the treated limb over and above the effects
388 common to both limbs.

389 390 *1.3.3 Comparative Analysis of Clinical Tremor Improvement*

391
392 Improvement (i.e. the difference between pre- and post-treatment TETRAS score) of the 5
393 individual tremor tasks and the average total score were compared to zero and between limbs
394 using two-sided Wilcoxon signed-rank tests ($\alpha=0.05$). To explore the differential impact of TAPS
395 on kinetic and postural tremors and how the improvement of each contributed to overall fTR,
396 measures of kinetic finger-to-nose tremor, spiral drawing tremor, and dot approximation tremor
397 were classified as kinetic tremor while forward postural and lateral postural tremor were grouped
398 as postural tremor.⁶ Subsequently, a multilinear regression (Matlab fitlm function) was used to
399 assess the relationship between fTR and the improvement in either kinetic or postural tremors
400 (Supplementary Eq. S2 A,B, $\alpha=0.05$). An analogous analysis was also done examining the
401 relationship between fTR and TETRAS scores of either tremor type before treatment, a proxy
402 for their initial tremor severity (Supplementary Eq. S2 C,D, $\alpha=0.05$).

403 404 *1.4 Phase 2: Intra-operative Thalamic Recording with Concurrent TAPS Treatment*

405
406 To assess if TAPS causally modulated broadband LFP or spiking activity in the contralateral
407 VIM, we acquired thalamic microelectrode recordings during the mapping phase of each
408 subject's awake DBS surgery (Fig. 2D). Each subject avoided tremor medications for at least 24
409 hours before their operation. Prior to initial sedation, we also fitted a wrist stimulator on their
410 dominant upper limb and verified median and radial hand dermatome paresthesia. Prior to the
411 mapping phase, remifentanyl sedation was discontinued for 15 minutes. During the mapping
412 phase, neural activity from the hemisphere contralateral to the dominant upper limb (i.e. limb
413 fitted with the wrist stimulator) was recorded from an array of 3 microelectrodes, 2 mm apart in
414 the anterior-posterior axis, along a trajectory beginning 10 mm above the target. Here, the
415 electrode in the center of the array was targeted to the VIM using consensus coordinates, 11
416 mm lateral to the wall of 3rd ventricle at the level of the AC-PC plane, 5.7 mm posterior to the
417 midcommissural point (i.e. $x=12$, $y=-5.7$, $z=0$; Fig. 3C).⁶⁰ To map the thalamic nuclei, the
418 borders of the ventralis oralis posterior, ventral intermediate, and ventral caudal nuclei were
419 determined based on neural responses evoked by motor, kinesthetic, and somatosensory
420 stimuli on the face and arms.⁶¹ At selected depths along trajectories planned for clinical
421 mapping of the relevant nuclei, 60 seconds of microelectrode recordings (MER) was collected
422 for each of two conditions: TAPS treatment ON and treatment OFF. With TAPS treatment ON,
423 subjects were stimulated in for 60 seconds using their calibrated stimulation amplitude and
424 alternating burst frequency from Phase 1. Bipolar neural recordings were made between each
425 microelectrode in the array and separate low impedance macroelectrodes located 1 cm dorsal
426 to the tip of the microelectrode. Signals were bandlimited at 20 kHz and digitized at 48 kHz
427 using the Guideline 4000 LP+ (FHC, Inc, Bodwin, ME).

428
429 Following the mapping procedure, short bouts of electrical stimulation (biphasic, cathode
430 leading 100 us pulses, 150 Hz, 0-4 mA current amplitude) were delivered through each of the 3

431 macroelectrodes to verify therapeutic efficacy of DBS and assess the resulting side effect
432 profile. The final implant location for the DBS lead was chosen to be region where: 1) test
433 stimulation resulted in the greatest tremor suppression, 2) test stimulation evoked minimal
434 therapy limiting side effects (i.e. paresthesia, muscle contractions and dysarthria), and 3) MER
435 revealed tremor cells and/or neural activity responsive to passive movement of the hand and
436 arm. Putatively this describes the optimal placement of VIM DBS leads for the treatment of ET,
437 projected to be in the ventral VIM 2-4 mm anterior to the border of the ventral caudal nucleus.⁶¹
438 For purposes of subsequent analyses, the final implant location is considered to be the
439 coordinates that described the placement of the distal edge of the most distal contact on the
440 DBS lead.

441 442 1.4.2 Characterizing Thalamic Local Field Potentials

443
444 Prior to analysis, raw MER were low pass filtered at 7500 Hz and motion artifacts were removed
445 with a custom algorithm that combined Banks et. al's method to ours own (see Supplementary
446 Methods 1.1, Supplementary Fig. S7).⁶² We also verified that turning TAPS ON did not induce
447 stimulation artifact in thalamic MER (Supplementary Fig. S8) Then, each 60-second MER time
448 series was segmented into 1-second bins and power spectral density (PSD) estimates were
449 computed using Thomson's multi-taper method with Slepian tapers (Matlab pmtm function, time-
450 half bandwidth product = 3). Next, area under the curve (AuC) of the PSD, i.e. power, was
451 calculated within canonical LFP frequency bands: delta (1-4 Hz), theta (4-8 Hz), alpha (8-12
452 Hz), beta (12-30 Hz), low gamma (30-70 Hz), and high gamma (70-200 Hz).⁶³⁻⁶⁶ For each LFP
453 frequency band in each 60-second MER time series, power was taken as the median values
454 after calculation was done for all 1-second bins. For each frequency band, we derived the LFP
455 modulation index (MI_{LFP}) to characterize how TAPS affect field potentials in the VIM. MI_{LFP} was
456 quantified as a fractional change in power (PSD AuC) of the TAPS treatment ON versus OFF
457 conditions (Fig. 3A, B):

$$458$$
$$459 \text{Modulation Index (MI)}_{LFP \text{ band}} = \frac{\text{Power}_{TAPS \text{ ON, banded}} - \text{Power}_{TAPS \text{ OFF, banded}}}{\text{Power}_{TAPS \text{ OFF, banded}}} \quad (\text{Eq. 2})$$

460 461 1.4.3 Characterizing Thalamic Neural Spiking Activities

462
463 We also examined the effect of TAPS on spiking activity (see Supplementary Methods 1.2).
464 Briefly, spike detection was performed by marking times where the preprocessed MER time
465 series rises above 5 standard deviations from the series' mean signal (Fig. 4A). Recordings with
466 likely multiunit activity were further filtered for if their spike rate was at least 1 Hz during the
467 treatment OFF condition. Next, spike times for each time series were binned (1 second bin
468 width) and a custom bootstrap resampling procedure was used to estimate the distribution of
469 spike rates (Fig. 4B). The firing rate of each example of multiunit activity was estimated as the
470 median of the bootstrapped distribution. Bootstrap resampling was done to reduce bias from
471 unequal time series duration after artifact removal. Similar to MI_{LFP} , we calculated the
472 modulation index for spiking activity (MI_{Spikes}) to quantify fractional changes during the TAPS
473 treatment ON versus OFF conditions (Fig. 4E, F):

$$474$$
$$475 \text{Modulation Index (MI)}_{Spikes} = \frac{\text{Spikes}_{TAPS \text{ ON}} - \text{Spikes}_{TAPS \text{ OFF}}}{\text{Spikes}_{TAPS \text{ OFF}}} \quad (\text{Eq. 3})$$

476 477 1.4.4 Comparative Analysis

478
479 Linear regression models were used to examine the relationship between either MI_{LFP} or MI_{Spikes}
480 and either the distance from the implant location (DIL, mm) (see Supplementary Methods 1.3) or

481 fractional tremor reduction (fTR) (Supplementary Eq. S3, S4). Histologically, the VIM measures
482 about 4 mm anteroposteriorly, 4 mm mediolaterally, and 6 mm dorsoventrally.^{67–69} Thus, we
483 approximated the diameter of the VIM to be 5 mm and segregated MER data at this threshold.
484 An $\alpha=0.05$ error rate was used for MI_{Spikes} comparisons. For MI_{LFP} comparisons, we further
485 applied a Bonferroni multi-comparison correction such that $\alpha'=0.008$ was used as the most
486 appropriate threshold of significance since regression for MI_{LFP} involved 6 bands. All analyses
487 and statistical comparisons were performed in MATLAB 2024a (Mathworks, Natick, MA).

488
489 ***Data availability***

490
491 Raw neural data structures are not openly available due to the inclusion of private health
492 information and are available from the corresponding author upon reasonable request. The de-
493 identified data supporting the findings of this study will be shared on DRYAD once accepted for
494 publication.

495 **References**

- 496 1. Song, P. *et al.* The global prevalence of essential tremor, with emphasis on age and sex: A
497 meta-analysis. *J. Glob. Health* **11**, 04028.
- 498 2. Thanvi, B., Lo, N. & Robinson, T. Essential tremor—the most common movement
499 disorder in older people. *Age Ageing* **35**, 344–349 (2006).
- 500 3. Bhatia, K. P. *et al.* Consensus Statement on the classification of tremors. from the task
501 force on tremor of the International Parkinson and Movement Disorder Society. *Mov.*
502 *Disord.* **33**, 75–87 (2018).
- 503 4. Louis, E. D. *et al.* Correlates of functional disability in essential tremor. *Mov. Disord.* **16**,
504 914–920 (2001).
- 505 5. Biary, N. & Koller, W. Kinetic predominant essential tremor: Successful treatment with
506 clonazepam. *Neurology* **37**, 471–471 (1987).
- 507 6. Charles, P. D., Esper, G. J., Davis, T. L., Maciunas, R. J. & Robertson, D. Classification of
508 Tremor and Update on Treatment. *Am. Fam. Physician* **59**, 1565–1572 (1999).
- 509 7. Elble, R. *et al.* Task force report: Scales for screening and evaluating tremor: Critique and
510 recommendations. *Mov. Disord.* **28**, 1793–1800 (2013).
- 511 8. Agarwal, S. & Biagioni, M. C. Essential Tremor. in *StatPearls* (StatPearls Publishing,
512 Treasure Island (FL), 2024).
- 513 9. Calzetti, S., Baratti, M., Gresty, M. & Findley, L. Frequency/amplitude characteristics of
514 postural tremor of the hands in a population of patients with bilateral essential tremor:
515 implications for the classification and mechanism of essential tremor. *J. Neurol.*
516 *Neurosurg. Psychiatry* **50**, 561–567 (1987).
- 517 10. Louis, E. D. *et al.* Heterotopic Purkinje Cells: a Comparative Postmortem Study of
518 Essential Tremor and Spinocerebellar Ataxias 1, 2, 3, and 6. *The Cerebellum* **17**, 104–
519 110 (2018).
- 520 11. Shill, H. A. *et al.* Pathologic findings in prospectively ascertained essential tremor
521 subjects. *Neurology* **70**, 1452–1455 (2008).
- 522 12. DeSimone, J. C., Archer, D. B., Vaillancourt, D. E. & Wagle Shukla, A. Network-level
523 connectivity is a critical feature distinguishing dystonic tremor and essential tremor.
524 *Brain* **142**, 1644–1659 (2019).
- 525 13. Roy, A. *et al.* Cortical dynamics within and between parietal and motor cortex in
526 essential tremor. *Mov. Disord.* **34**, 95–104 (2019).
- 527 14. Dum, R. P. & Strick, P. L. An Unfolded Map of the Cerebellar Dentate Nucleus and its
528 Projections to the Cerebral Cortex. *J. Neurophysiol.* **89**, 634–639 (2003).
- 529 15. Mai, J. K. & Majtanik, M. Toward a Common Terminology for the Thalamus. *Front.*
530 *Neuroanat.* **12**, (2019).
- 531 16. Evarts, E. V. & Tanji, J. Reflex and intended responses in motor cortex pyramidal tract
532 neurons of monkey. *J. Neurophysiol.* **39**, 1069–1080 (1976).
- 533 17. Thach, W. T. Correlation of neural discharge with pattern and force of muscular activity,
534 joint position, and direction of intended next movement in motor cortex and
535 cerebellum. *J. Neurophysiol.* **41**, 654–676 (1978).
- 536 18. Strick, P. L. Cerebellar involvement in volitional muscle responses to load changes. in
537 *Cerebral Motor Control in Man: Long Loop Mechanisms* vol. 4 (Karger, Basel, 1978).

- 538 19. Suminski, A. J., Rao, S. M., Mosier, K. M. & Scheidt, R. A. Neural and electromyographic
539 correlates of wrist posture control. *J. Neurophysiol.* **97**, 1527–1545 (2007).
- 540 20. Suminski, A. J., Doudlah, R. C. & Scheidt, R. A. Neural Correlates of Multisensory
541 Integration for Feedback Stabilization of the Wrist. *Front. Integr. Neurosci.* **16**, (2022).
- 542 21. Haubenberger, D. & Hallett, M. Essential Tremor. *N. Engl. J. Med.* **378**, 1802–1810
543 (2018).
- 544 22. Louis, E. D., Rios, E. & Henchcliffe, C. How are we doing with the treatment of essential
545 tremor (ET)? *Eur. J. Neurol.* **17**, 882–884 (2010).
- 546 23. Soto, M. C. S. Essential tremor: New advances. (2020).
- 547 24. Dallapiazza, R. F. *et al.* Outcomes from stereotactic surgery for essential tremor. *J.*
548 *Neurol. Neurosurg. Psychiatry* **90**, 474–482 (2019).
- 549 25. Kim, M.-R. *et al.* Patients’ reluctance to undergo deep brain stimulation for Parkinson’s
550 disease. *Parkinsonism Relat. Disord.* **23**, 91–94 (2016).
- 551 26. Elias, W. J. *et al.* A Pilot Study of Focused Ultrasound Thalamotomy for Essential
552 Tremor. *N. Engl. J. Med.* **369**, 640–648 (2013).
- 553 27. Elias, W. J. *et al.* A Randomized Trial of Focused Ultrasound Thalamotomy for Essential
554 Tremor. *N. Engl. J. Med.* **375**, 730–739 (2016).
- 555 28. Cosgrove, G. R. *et al.* Magnetic resonance imaging–guided focused ultrasound
556 thalamotomy for essential tremor: 5-year follow-up results. *J. Neurosurg.* **138**, 1028–
557 1033 (2022).
- 558 29. Park, Y.-S., Jung, N. Y., Na, Y. C. & Chang, J. W. Four-year follow-up results of magnetic
559 resonance-guided focused ultrasound thalamotomy for essential tremor. *Mov. Disord.*
560 **34**, 727–734 (2019).
- 561 30. Bruno, F. *et al.* MRgFUS thalamotomy for the treatment of tremor: evaluation of learning
562 curve and operator’s experience impact on the procedural and clinical outcome. *Acta*
563 *Neurochir. (Wien)* **165**, 727–733 (2023).
- 564 31. FDA. DEN170028. *Device Classification Under Section 513(f)(2)(De Novo)*
565 [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN1700](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN170028)
566 28.
- 567 32. Fukushima, T., Mayanagi, Y. & Bouchard, G. Thalamic evoked potentials to
568 somatosensory stimulation in man. *Electroencephalogr. Clin. Neurophysiol.* **40**, 481–
569 490 (1976).
- 570 33. Hernandez-Martin, E., Arguelles, E., Deshpande, R. & Sanger, T. D. Evoked Potentials
571 During Peripheral Stimulation Confirm Electrode Location in Thalamic Subnuclei in
572 Children With Secondary Dystonia. *J. Child Neurol.* **35**, 799–807 (2020).
- 573 34. Tsuji, S., Shibasaki, H., Kato, M., Kuroiwa, Y. & Shima, F. Subcortical, thalamic and
574 cortical somatosensory evoked potentials to median nerve stimulation.
575 *Electroencephalogr. Clin. Neurophysiol. Potentials Sect.* **59**, 465–476 (1984).
- 576 35. Popovych, O. V. & Tass, P. A. Control of Abnormal Synchronization in Neurological
577 Disorders. *Front. Neurol.* **5**, 268 (2014).
- 578 36. Pahwa, R. *et al.* An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve
579 Stimulation in Essential Tremor. *Neuromodulation Technol. Neural Interface* **22**, 537–
580 545 (2019).

- 581 37. Isaacson, S. H. *et al.* Prospective Home-use Study on Non-invasive Neuromodulation
582 Therapy for Essential Tremor. *Tremor Hyperkinetic Mov. N. Y. N* **10**, 29 (2020).
- 583 38. Lu, C., Khosla, D., Kent, A., Bronte-Stewart, H. M. & Rosenbluth, K. H. Transcutaneous
584 Afferent Patterned Stimulation for Essential Tremor: Real-World Evidence with Long
585 Term Follow-Up. *Tremor Hyperkinetic Mov.* **13**, 29 (2023).
- 586 39. Pascual-Valdunciel, A. Non-invasive electrical stimulation of peripheral nerves for the
587 management of tremor. *J. Neurol. Sci.* (2022).
- 588 40. Wagle Shukla, A. Rationale and Evidence for Peripheral Nerve Stimulation for Treating
589 Essential Tremor. *Tremor Hyperkinetic Mov.* **12**, 20.
- 590 41. Barath, A. S. *et al.* Brain Metabolic Changes with Longitudinal Transcutaneous Afferent
591 Patterned Stimulation in Essential Tremor Subjects. *Tremor Hyperkinetic Mov. N. Y. N*
592 **10**, 52 (2020).
- 593 42. Gironell, A., Ribosa-Nogué, R., Gich, I., Marin-Lahoz, J. & Pascual-Sedano, B. Severity
594 Stages in Essential Tremor: A Long-Term Retrospective Study Using the Glass Scale.
595 *Tremor Hyperkinetic Mov.* **5**, 299 (2015).
- 596 43. Louis, E. D. & Faust, P. L. Essential tremor: the most common form of cerebellar
597 degeneration? *Cerebellum Ataxias* **7**, 1–10 (2020).
- 598 44. Molnar, G. F., Pilliar, A., Lozano, A. M. & Dostrovsky, J. O. Differences in Neuronal Firing
599 Rates in Pallidal and Cerebellar Receiving Areas of Thalamus in Patients With
600 Parkinson’s Disease, Essential Tremor, and Pain. *J. Neurophysiol.* **93**, 3094–3101 (2005).
- 601 45. Pedrosa, D. J. *et al.* Essential tremor and tremor in Parkinson’s disease are associated
602 with distinct ‘tremor clusters’ in the ventral thalamus. *Exp. Neurol.* **237**, 435–443
603 (2012).
- 604 46. Kane, A., Hutchison, W. D., Hodaie, M., Lozano, A. M. & Dostrovsky, J. O. Enhanced
605 synchronization of thalamic theta band local field potentials in patients with essential
606 tremor. *Exp. Neurol.* **217**, 171–176 (2009).
- 607 47. Filip, P., Lungu, O. V., Manto, M.-U. & Bareš, M. Linking Essential Tremor to the
608 Cerebellum: Physiological Evidence. *The Cerebellum* **15**, 774–780 (2016).
- 609 48. Hua, S. E. & Lenz, F. A. Posture-Related Oscillations in Human Cerebellar Thalamus in
610 Essential Tremor Are Enabled by Voluntary Motor Circuits. *J. Neurophysiol.* **93**, 117–127
611 (2005).
- 612 49. Pesaran, B. Neural correlations, decisions, and actions. *Curr. Opin. Neurobiol.* **20**, 166–
613 171 (2010).
- 614 50. Peng-Chen, Z. *et al.* Unilateral thalamic deep brain stimulation in essential tremor
615 demonstrates long-term ipsilateral effects. *Parkinsonism Relat. Disord.* **19**, 1113–1117
616 (2013).
- 617 51. Lin, Z., Zhang, C., Li, D. & Sun, B. Lateralized effects of deep brain stimulation in
618 Parkinson’s disease: evidence and controversies. *Npj Park. Dis.* **7**, 1–8 (2021).
- 619 52. Österlund, E., Blomstedt, P. & Fytagoridis, A. Ipsilateral Effects of Unilateral Deep Brain
620 Stimulation for Essential Tremor. *Stereotact. Funct. Neurosurg.* **100**, 248–252 (2022).
- 621 53. Kim, M. J., Jeon, S. R., Kim, S. R., Lee, M. C. & Chung, S. J. Lateralized Effects of
622 Unilateral Thalamotomy and Thalamic Stimulation in Patients with Essential Tremor. *J.*
623 *Mov. Disord.* **4**, 64 (2011).

- 624 54. Nicolai, E. N. *et al.* Sources of off-target effects of vagus nerve stimulation using the
625 helical clinical lead in domestic pigs. *J. Neural Eng.* **17**, 046017 (2020).
- 626 55. Chang, Y.-C. *et al.* Quantitative estimation of nerve fiber engagement by vagus nerve
627 stimulation using physiological markers. *Brain Stimulat.* **13**, 1617–1630 (2020).
- 628 56. Michelsen, L. G. & Hug, C. C. The pharmacokinetics of remifentanyl. *J. Clin. Anesth.* **8**,
629 679–682 (1996).
- 630 57. Bos, M. J. *et al.* Effect of Anesthesia on Microelectrode Recordings During Deep Brain
631 Stimulation Surgery: A Narrative Review. *J. Neurosurg. Anesthesiol.* **33**, 300 (2021).
- 632 58. Lin, P. T. *et al.* Noninvasive neuromodulation in essential tremor demonstrates relief in a
633 sham-controlled pilot trial. *Mov. Disord.* **33**, 1182–1183 (2018).
- 634 59. Tröster, A. I., Pahwa, R., Fields, J. A., Tanner, C. M. & Lyons, K. E. Quality of life in
635 Essential Tremor Questionnaire (QUEST): Development and initial validation.
636 *Parkinsonism Relat. Disord.* **11**, 367–373 (2005).
- 637 60. Wakim, A. A. *et al.* Direct targeting of the ventral intermediate nucleus of the thalamus
638 in deep brain stimulation for essential tremor: a prospective study with comparison to a
639 historical cohort. *J. Neurosurg.* **136**, 662–671 (2022).
- 640 61. Gross, R. E., Krack, P., Rodriguez-Oroz, M. C., Rezai, A. R. & Benabid, A.-L.
641 Electrophysiological mapping for the implantation of deep brain stimulators for
642 Parkinson’s disease and tremor. *Mov. Disord.* **21**, S259–S283 (2006).
- 643 62. Banks, M. I. *et al.* Functional geometry of auditory cortical resting state networks
644 derived from intracranial electrophysiology. *PLOS Biol.* **21**, e3002239 (2023).
- 645 63. Thompson, J. A., Lanctin, D., Ince, N. F. & Abosch, A. Clinical Implications of Local Field
646 Potentials for Understanding and Treating Movement Disorders. *Stereotact. Funct.*
647 *Neurosurg.* **92**, 251–263 (2014).
- 648 64. Ray, S., Crone, N. E., Niebur, E., Franaszczuk, P. J. & Hsiao, S. S. Neural Correlates of
649 High-Gamma Oscillations (60–200 Hz) in Macaque Local Field Potentials and Their
650 Potential Implications in Electrocorticography. *J. Neurosci.* **28**, 11526–11536 (2008).
- 651 65. Womelsdorf, T. *et al.* Modulation of Neuronal Interactions Through Neuronal
652 Synchronization. *Science* **316**, 1609–1612 (2007).
- 653 66. Schoffelen, J.-M., Oostenveld, R. & Fries, P. Neuronal Coherence as a Mechanism of
654 Effective Corticospinal Interaction. *Science* **308**, 111–113 (2005).
- 655 67. Hirai, T., Ohye, C., Nagaseki, Y. & Matsumura, M. Cytometric analysis of the thalamic
656 ventralis intermedius nucleus in humans. *J. Neurophysiol.* **61**, 478–487 (1989).
- 657 68. Morel, A., Magnin, M. & Jeanmonod, D. Multiarchitectonic and stereotactic atlas of the
658 human thalamus. *J. Comp. Neurol.* **387**, 588–630 (1997).
- 659 69. Najdenovska, E. *et al.* Comparison of MRI-based automated segmentation methods
660 and functional neurosurgery targeting with direct visualization of the Ventro-
661 intermediate thalamic nucleus at 7T. *Sci. Rep.* **9**, 1119 (2019).
- 662

663 **Table**


Table 1. Demographic, Baseline Severity, and TAPS Settings

Subject	1	2	3	4	5	6	7	8	9	Cohort Summary
Age (decade)	50s	70s	70s	60s	50s	70s	60s	60s	60s	65 ± 7
Sex	M	M	F	M	M	M	M	F	M	Male: 78%
Age of Onset (decade)	10s	10s	60s	30s	20s	10s	20s	40s	50s	29 ± 17
Family History	1	1	0	1	1	1	0	0	0	56%
Specific Current Co-Therapy										
Propranolol	1	1	1	0	0	1	0	1	1	67%
Primidone	1	1	1	0	0	0	0	0	0	33%
Gabapentin	0	1	1	0	0	0	0	0	0	22%
Initial QUEST Life Disability Scores (Frequency Range: 0-100%)										
Tremor During Waking Hours	89	83	56	89	89	89	94	94	56	82.1 ± 15.4
Communication	17	0	0	67	0	42	25	0	25	19.5 ± 23.2
Work and Finance	50	0	38	8	42	67	33	0	8	27.3 ± 24
Hobbies and Leisure	83	92	100	100	75	100	58	92	67	85.2 ± 15.5
Physical	64	28	100	64	31	97	75	78	58	66.1 ± 25.2
Psychosocial	61	17	58	33	39	31	64	28	8	37.7 ± 19.8
Initial TETRAS Scores (Averaged Across Tasks, Severity Range: 0-4)										
Archimedes Spiral (Task 6)	3.0	3.0	4.0	2.0	2.0	2.0	3.0	4.0	2.0	2.8 ± 0.8
Upper Limb Tremor (Tasks 4, 6, 8)	2.0	2.4	3.1	1.7	2.0	2.1	2.7	3.0	1.8	2.3 ± 0.5
Total Task Score (Tasks 1-9)	1.7	1.5	2.2	1.5	1.5	1.3	1.7	2.2	1.0	1.6 ± 0.4
TAPS Settings										
Dominant Hand	Right	Left	Right	Left	Right	Right	Right	Right	Right	Right: 78%
Tremor Frequency (Hz)	5.4	4.5	4.5	4.5	5.7	8.1	5.3	6.5	4.1	5.4 ± 1.3
Stimulation Current (mA)	7.0	7.0	6.5	7.3	5.8	6.5	7.8	6.0	9.5	7.0 ± 1.1


Range displayed as mean ± 1 standard deviation.

664

665 **Figures**
666




667
668 **Figure 1. Investigating the effect of TAPS on clinical tremor scores and thalamus neural**
669 **activity in essential tremor patients.**
670 **A** Demonstration of the wrist stimulation band placement on the dominant hand, showing the 3
671 electrodes used for the TAPS paradigm. Stimulator unclashed from the dorsal wrist, seen more
672 clearly in **(C)**. **B** TAPS delivers alternating pulse trains to the median and radial nerves at a
673 burst frequency matched to each patient's tremor frequency. Stimulation amplitude is set to the
674 maximum tolerable level reported by each patient. **C** During phase 1 (pre-operative), tremor
675 severity is assessed using TETRAS scores before and after a 40-minute TAPS session. **D**
676 During phase 2 (intra-operative), MER are collected along the planned DBS trajectory targeting
677 the VIM nucleus of the thalamus, with TAPS alternating between the ON and OFF states.




678
679 **Figure 2. TAPS treatment improves essential tremor symptoms, with enhanced impact on**
680 **kinetic tremor relative to postural tremor in the treated limb (n=8).**

681 **A** Mean \pm SEM improvement in average upper limb tremor scores after 40 minutes of TAPS
682 treatment, comparing the treated versus untreated limb across all patients (*two-sided signed-
683 rank $p=0.029$). **B–C** Representative examples showing changes in spiral consistency and
684 amplitude following TAPS treatment in patients with **(B)** low fTR (cyan) and **(C)** high fTR
685 (orange). **D–E** Multiple linear regression analyses showing the relationship between fTR and
686 aggregated improvement in **(D)** kinetic tremor tasks and **(E)** postural tremor tasks. To visualize
687 the regression model, the x-axis rescales the combined effect of all independent variables,
688 adjusted using the Frisch–Waugh–Lovell theorem (Matlab fitm).



689
 690
 691 **Figure 3. TAPS treatment modulates thalamic local field potentials with varied effects**
 692 **based on location and degree of tremor control.**
 693 **A–B** Representative power spectral density (PSD) estimates comparing **(A)** low α -band
 694 modulation index ($MI_{LFP-\alpha}$) in a patient with low fTR (cyan) versus **(B)** high $MI_{LFP-\alpha}$ in a patient
 695 with high fTR (orange). Black and gray lines show Treatment ON and OFF conditions,
 696 respectively. **C** Schematic illustrating MER distance relative to the final implant location within
 697 the thalamus (defined as the distal edge of the DBS lead's distal contact). MER locations are
 698 classified as within VIM (red) or outside VIM (blue). **D–E** Correlation between $MI_{LFP-\alpha}$ and
 699 distance from implant location (DIL) for recordings within VIM (red) and outside VIM (blue)
 700 ($n=8$). Points indicate MER data from individual depths, superimposed by best-fit lines and 95%
 701 confidence intervals. **F** Mean regression slope coefficients ± 2 SEM showing the relationship
 702 between $MI_{LFP-Band}$ and DIL for recordings within VIM (red) and outside VIM (blue). \S indicates
 703 regression slope coefficient with $p \leq 0.008$ (Bonferroni-corrected α' threshold). (See
 704 supplementary Fig. S5 for expanded regression plots.) **G–H** Correlation between $MI_{LFP-\alpha}$ and
 705 fTR for recordings within VIM (red) and outside VIM (blue). **I** Mean regression slope coefficients
 706 ± 2 SEM showing the relationship between $MI_{LFP-Band}$ and fTR for recordings within VIM (red)
 707 and outside VIM (blue). \S indicates regression slope coefficient with $p \leq 0.008$ (Bonferroni-
 708 corrected α' threshold). (See supplementary Fig. S6 for expanded regression plots.)



709
710
711
712
713
714
715
716
717
718
719
720
721

Figure 4. Modulation of spiking activity in thalamic MER under TAPS treatment ON and OFF conditions.

A–B Sample time series of multiunit activity recorded 0.5 mm from the final implant location within the VIM thalamus during TAPS treatment **(A)** OFF and **(B)** ON periods. Spike rates (Hz) were calculated in consecutive, non-overlapping 1-second segments of the recordings, then aggregated for bootstrap resampling. **C–D** Spike rate distributions obtained through 10,000 bootstrap resampling iterations of the rates collected from recordings shown in **(A)** and **(B)**, during TAPS **(C)** OFF and **(D)** ON conditions, respectively. Vertical lines indicate median spike rates, representing the most likely spike rate for each recording. **E–F** Simple linear correlations between MI_{Spikes} and **(E)** DIL or **(F)** fTR. Data points represent individual recordings taken ≤ 5 mm from the implant location (red) with baseline spike rates >1 Hz during TAPS OFF. Best-fit lines with 95% confidence intervals are shown.